COVID-19 proficiency testing
May 2020—The CAP has released a new proficiency testing program for the detection of SARS-CoV-2 by nucleic acid amplification testing.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
EKF launches β-ketone, glucose POC analyzer
May 2020—EKF Diagnostics has launched in the United States its Stat-Site WB dual-use whole blood β-ketone and glucose meter for professional use in the management of diabetes. The CLIA-waived handheld analyzer quantitatively measures β-ketone (beta-hydroxybutyrate) from fresh capillary and venous whole blood in 10 seconds and delivers quantitative measurements in five seconds for glucose in fresh capillary, venous, and neonatal whole blood. The system has a measurement range of 0.1–8.0 mmol/L for β-ketone and 0.5–33.3 mmol/L for blood glucose. Its hematocrit range is 10–70 percent for β-ketone and 20–70 percent for blood glucose.
BD Kiestra ReadA device listed with the FDA
May 2020—BD announced that its BD Kiestra ReadA is device listed with the FDA. The BD Kiestra ReadA incubation and imaging system, which is available as a standalone instrument, aims to help improve operational efficiency in clinical microbiology laboratories by automating routine plate management tasks and delivering accuracy through standardized digital image acquisition. BD, 201-847-6800
MilliporeSigma to manufacture Elypta liquid biopsy kits
May 2020—MilliporeSigma has been selected by Swedish molecular diagnostics company Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits. The kits analyze metabolites deregulated in several cancer types and will initially be made available for research use only. They are intended for mass spectrometry systems and will allow qualified researchers to measure the full spectrum of human glycosaminoglycans in body fluid samples.
Viracor Eurofins gets EUA for SARS-CoV-2 LDT
May 2020—Viracor Eurofins was granted FDA emergency use authorization for the Viracor SARS-CoV-2 assay, a real-time polymerase chain reaction test intended for the qualitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swab, nasal swab, nasopharyngeal wash, nasal wash, oropharyngeal swab, and bronchoalveolar lavage from individuals suspected of having COVID-19.
Ortho launches second COVID-19 antibody test
May 2020—Ortho Clinical Diagnostics announced the FDA granted emergency use authorization to its second COVID-19 antibody test—the Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test. The test demonstrated 100 percent specificity and runs on Ortho’s high-throughput, fully automated analyzers including its Vitros XT 7600 integrated system, Vitros 3600 immunodiagnostic system, Vitros 5600 integrated system, and it will soon be available on Vitros ECi/ECiQ immunodiagnostic systems.
Thermo Fisher, Janssen to co-develop cancer CDx
May 2020—Thermo Fisher Scientific has signed an agreement with Janssen Biotech to co-develop a companion diagnostic in oncology. The diagnostic will support clinical trial enrollment worldwide.
Horizon CHOsource platform
May 2020—Horizon Discovery Group announced its cGMP-compliant CHOsource platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s Chinese hamster ovary cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, the company reported in a press statement, enabling Immutep and Batavia Biosciences to reach a milestone in the preclinical development of the compound.
New books: pathology art, atlas, endocrine guide
April 2020—Sylvia L. Asa, MD, PhD, consultant in endocrine pathology, University Hospitals Cleveland Medical Center and University Health Network Toronto, and professor of pathology, Case Western Reserve University, served as an editor of two recently published books related to pathology and is a coauthor of the first book in series five of the AFIP Atlas of Tumor and Non-Tumor Pathology series. Dr. Asa showcased these books at this year’s USCAP meeting in Los Angeles. Art Gallery of Pathology (ARP Press), created by Tim-Rasmus Kiehl, MD, and edited by Dr. Asa, explores the use of human pathology samples as they are used to create art. Dr. Kiehl worked as a neuropathologist at University Health Network in Toronto.
Randox STI assay gets CE mark
April 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample. It tests simultaneously for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Treponema pallidum, HSV-1, HSV-2, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.